BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HY1272 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HY1272\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06218940-2526@assetmemo.bio
DTSTAMP:20261121T005443Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:HY1272: Phase 1 readout est. (NCT06218940)
DESCRIPTION:HY1272\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: HY1272 i
 n Patients With Locally Advanced or Metastatic Solid Tumors or Locally Adv
 anced or Metastatic EGFRm+ NSCLC\nEstimated primary completion: 1 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/hy1272#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06218940
URL:https://assetmemo.bio/drug/hy1272#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
